Skip to main content
Caplight Logo









Elisigen

Elisigen

Private
SeoulEnterprise Softwarehttps://elisigen.com/

Last Round

Series C

Jan 19, 2026

Est. Valuation

$179M

Total Funding Raised

$78.45M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Elisigen is a biotechnology company that develops AAV-based gene therapies to treat retinal and neurological diseases.

Sector

Enterprise Software

Verticals

Workflow Automation, Project Management, Platform-as-a-Service

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapybiotechnologyAAV therapydrug discoveryclinical trialsbiopharmavector engineeringretinal diseaseneurological diseasebiotech startupclinical-stage biotechR&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elisigen Comparables

Compare Elisigen with similar companies based on industry and business-model similarity.

Elisigen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Elisigen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 19, 2026
Series BJun 3, 2021
Series AApr 30, 2019
SeedOct 25, 2018

Elisigen Investors

Notable investors and investment history

Elisigen investors
InvestorRounds
SV InvestmentSeries B
KB InvestmentSeries C
Seven Tree Equity PartnersSeries B
Ulmus InvestmentSeries B
Premier PartnersSeries C
NICE F&ISeries C
QUAD Investment ManagementSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    $29M round with participation from NH Investment & Securities and Premier Partners.

  • May 21, 2024

    Grew 67% QoQ, from 6 to 10 employees.

Elisigen Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elisigen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elisigen's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range11
Year Founded2018
Last FundingJan 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?